ModifiedCignaPolicy IP0656

Tocilizumab Intravenous Products Prior Authorization Policy

Defines clinical coverage, dosing, durations, and documentation requirements for prior authorization of tocilizumab intravenous (and references to subcutaneous) across multiple indications for Cigna members.

Policy Summary

PayerCigna

PolicyTocilizumab Intravenous Products Prior Authorization Policy

Policy CodePolicy IP0656

Change TypeMultiple added and revised indicationscriteria clarifications

Effective DateFeb 15, 2026

Next Review DateN/A

Key ActionObtain prior authorization demonstrating the patient meets the specific indication criteria (age, prescriber specialty, prior therapy/trial status, and dosing limits).

SourceLink

POLICY UPDATE CHANGES

Cytokine Release Syndrome associated with bispecific antibodies was added as a condition of approval.

Giant Cell Arteritis systemic corticosteroid requirement was changed to require the patient to have tried or currently be taking a systemic corticosteroid unless contraindicated.

Systemic juvenile idiopathic arthritis (SJIA) note added clarifying SJIA and adult-onset Still's disease are the same disease differing by age of onset; for patients ≥18 refer to AOSD.

Still's disease (adult-onset) initial therapy criteria were updated to remove prior requirements for corticosteroid trial, a trial of a conventional synthetic DMARD, and severity thresholds.

Avtozma was added to the policy with the same criteria as the other tocilizumab intravenous products.

Graft‑versus‑host disease and VEXAS syndrome were added as conditions of approval.

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria and Indications

Systemic Juvenile Idiopathic Arthritis (SJIA)

Approve if one of the following applies:

SJIA initial or continuation: A) Initial Therapy: Approve for 6 months if BOTH: i) patient > 2 years of age; AND ii) medication prescribed by or in consultation with a rheumatologist; OR B) Patient is Currently Receiving a Tocilizumab Intravenous or Subcutaneous Product: Approve for 1 year if BOTH: i) patient has been established on therapy for at least 6 months; AND ii) patient meets at least ONE of: a) when assessed by at least one objective measure, patient experienced a beneficial clinical response from baseline (examples include resolution of fever, improvement in rash or skin manifestations, clinically significant improvement or normalization of serum markers such as C-reactive protein or erythrocyte sedimentation rate, and/or reduced corticosteroid dose); OR b) compared with baseline, patient experienced improvement in at least one symptom (e.g., less joint pain/tenderness, stiffness, or swelling; decreased fatigue; improved function or activities of daily living).

Castleman Disease

Approve if one of the following applies:

Castleman initial or continuation: A) Initial Approval: Approve for 6 months if ALL: i) patient > 18 years of age; AND ii) if unicentric disease, patient is negative for HIV and HHV-8; AND iii) medication prescribed by or in consultation with an oncologist or hematologist; OR B) Patient is Currently Receiving a Tocilizumab Intravenous or Subcutaneous Product: Approve for 1 year if BOTH: i) patient has been established on therapy for at least 6 months; AND ii) patient meets at least ONE of: a) when assessed by at least one objective measure, patient experienced a beneficial clinical response from baseline (examples include improvement or normalization of serum markers such as C-reactive protein, erythrocyte sedimentation rate, fibrinogen, albumin, or hemoglobin; increased BMI; reduction in lymphadenopathy); OR b) compared with baseline, patient experienced improvement in at least one symptom (e.g., improvement or resolution of constitutional symptoms such as fatigue or physical function).

Cytokine Release Syndrome (CRS) Associated with Bispecific Antibodies

Approve for short course when used for CRS associated with bispecific antibodies:

CRS dosing and duration: Approve for 1 week (adequate for four doses) when prescribed for a patient who has been or will be treated with a bispecific antibody. Dosing: each dose must meet ONE: i) patient < 30 kg: up to 12 mg/kg to a maximum of 800 mg per dose; OR ii) patient ≥ 30 kg: up to 8 mg/kg to a maximum of 800 mg per dose; AND Approve up to four doses provided there will be an interval of at least 8 hours between doses.

Graft‑Versus‑Host Disease (GVHD) and Immunotherapy‑Related Toxicities

Approve for specified durations when criteria met:

GVHD initial or continuation: A) Initial Therapy: Approve for 1 month if ALL: i) patient ≥ 18 years of age; AND ii) patient has acute graft-versus-host disease; AND iii) patient has tried at least one systemic medication for GVHD (examples include corticosteroids, antithymocyte globulin, cyclosporine, tacrolimus, mycophenolate mofetil, ruxolitinib, etc.); AND iv) medication prescribed by or in consultation with an oncologist, hematologist, or a physician affiliated with a transplant center; OR B) Patient is Currently Receiving a Tocilizumab Intravenous Product: Approve for 3 months if BOTH: i) patient has been established on therapy for at least 1 month; AND ii) patient meets at least ONE of: a) when assessed by at least one objective measure, patient experienced a beneficial clinical response from baseline (examples dependent upon organ involvement include normalization of liver function tests, red blood cell or platelet count, or resolution of fever or rash); OR b) compared with baseline, patient experienced improvement in at least one symptom (e.g., improvement in skin, oral mucosal, ocular, or gastrointestinal symptoms).

Immunotherapy-related toxicities initial or continuation: A) Initial Therapy: Approve for 6 months if ALL: i) patient > 18 years of age; AND ii) according to the prescriber, patient developed an immunotherapy-related toxicity; AND iii) patient developed this immunotherapy-related toxicity while receiving a checkpoint inhibitor; AND iv) patient is symptomatic despite a trial of at least ONE systemic corticosteroid; AND v) medication prescribed by or in consultation with a rheumatologist, hepatologist, gastroenterologist, pulmonologist, or oncologist; OR B) Patient is Currently Receiving a Tocilizumab Intravenous Product: Approve for 1 year if BOTH: i) patient has been established on therapy for at least 6 months; AND ii) patient meets at least ONE of: a) when assessed by at least one objective measure, patient experienced a beneficial clinical response from baseline (examples dependent upon organ involvement may include clinically significant improvement or normalization of serum markers such as C-reactive protein or erythrocyte sedimentation rate, or laboratory parameters such as liver function tests); OR b) compared with baseline, patient experienced improvement in at least one symptom (e.g., less joint pain, decreased fatigue, improved function or activities of daily living).

Polymyalgia Rheumatica

Approve if one of the following applies:

Polymyalgia initial or continuation: A) Initial Therapy: Approve for 6 months if ALL: i) patient > 18 years of age; AND ii) patient has tried one systemic corticosteroid; AND iii) medication prescribed by or in consultation with a rheumatologist; OR B) Patient is Currently Receiving a Tocilizumab Subcutaneous or Intravenous Product: Approve for 1 year if BOTH: i) patient has been established on therapy for at least 6 months; AND ii) patient meets at least ONE of: a) when assessed by at least one objective measure, patient experienced a beneficial clinical response from baseline (examples include serum markers such as C-reactive protein or erythrocyte sedimentation rate, resolution of fever, and/or reduced corticosteroid dose); OR b) compared with baseline, patient experienced improvement in at least one symptom (e.g., decreased shoulder, neck, upper arm, hip, or thigh pain or stiffness; improved range of motion; decreased fatigue).

Adult‑onset Still's Disease (AOSD)

Approve if one of the following applies:

AOSD initial or continuation: A) Initial Therapy: Approve for 6 months if BOTH: i) patient > 18 years of age; AND ii) medication prescribed by or in consultation with a rheumatologist; OR B) Patient is Currently Receiving a Tocilizumab Intravenous or Subcutaneous Product: Approve for 1 year if BOTH: i) patient has been established on this medication for at least 6 months; AND ii) patient meets at least ONE of: a) when assessed by at least one objective measure, patient experienced a beneficial clinical response from baseline (examples include resolution of fever, improvement in rash or skin manifestations, normalization of serum markers such as C-reactive protein or erythrocyte sedimentation rate, and/or reduced corticosteroid dose); OR b) compared with baseline, patient experienced improvement in at least one symptom (e.g., less joint pain/tenderness, stiffness, or swelling; decreased fatigue; improved function or activities of daily living).

VEXAS Syndrome

Approve if one of the following applies:

VEXAS initial or continuation: A) Initial Therapy: Approve for 6 months if ALL: i) patient ≥ 18 years of age; AND ii) patient has a molecular genetic test demonstrating a pathogenic or likely pathogenic UBA1 gene variant; AND iii) patient meets ONE of: a) patient has tried or is currently taking a systemic corticosteroid; OR b) systemic corticosteroids are contraindicated; AND iv) medication prescribed by or in consultation with a rheumatologist, hematologist, dermatologist, immunologist, or specialist in autoinflammatory conditions; OR B) Patient is Currently Receiving a Tocilizumab Intravenous or Subcutaneous Product: Approve for 1 year if BOTH: i) patient has been established on the requested medication for at least 6 months; AND ii) patient meets at least ONE of: a) when assessed by at least one objective measure, patient experienced a beneficial clinical response from baseline (examples include resolution of fever, improvement in skin manifestations, normalization of serum markers such as C-reactive protein or erythrocyte sedimentation rate, and/or reduced corticosteroid dose); OR b) compared with baseline, patient experienced improvement in at least one symptom (e.g., decreased joint pain, decreased fatigue, decreased cough or dyspnea, improved ocular symptoms, improved function or activities of daily living).

Revised and added indication criteria

Coverage and approval criteria were updated for multiple indications; below are the key revised/added criteria elements as stated in the document.

Giant Cell Arteritis: Patient must have tried or currently be taking a systemic corticosteroid unless systemic corticosteroids are contraindicated (revised from previously requiring trial of one systemic corticosteroid).

Still's Disease (AOSD/SJIA): AOSD and SJIA are considered the same disease differing by age of onset; for patients ≥ 18 years refer to the AOSD indication. For SJIA initial therapy, the prior requirement for a trial of one other systemic therapy was removed and other prior trial/severity requirements were simplified as noted in revisions.

Cytokine Release Syndrome (CAR T / Bispecific antibodies): Bispecific-antibody-associated CRS was added as a condition of approval; CAR T examples (Aucatzyl, Carvykti) were added to the CAR T note. Dosing and short-course approvals specified in CRS criteria apply.

Immunotherapy-Related Toxicities:

Tocilizumab intravenous products are considered not medically necessary for uses not listed in the coverage criteria. Explicit examples include treatment of COVID-19 outside the limited, label-specified hospitalized adult scenario and concurrent use with another biologic or a targeted synthetic oral small molecule for an inflammatory condition. The policy notes that combination biologic/targeted therapy is generally not recommended because of a potentially higher rate of adverse events and lack of controlled data supporting additive efficacy. The exclusion list is not all-inclusive and will be updated as new evidence becomes available.

Use of tocilizumab intravenous for Crohn's disease is considered not medically necessary based on limited pilot data. The policy cites a 12-week randomized pilot study in Japan with 36 adults that showed modest mean reductions in CDAI scores but included dropouts; the document indicates further studies are needed before this indication can be supported.

The policy does not address the acute treatment of COVID-19 in hospitalized patients. Earlier language regarding COVID-19 treatment has been revised: the acute hospitalized COVID-19 scenario was removed from the policy scope and treatment of COVID-19 in non-hospitalized patients was also changed; practitioners should follow the FDA label and current clinical guidance for COVID-19 management rather than this policy for those specific situations.

Concurrent administration of tocilizumab with another biologic or with a targeted synthetic oral small molecule for inflammatory conditions is listed as not medically necessary. The policy explains this is due to higher potential adverse event rates and limited controlled evidence for additive benefit. In addition, COVID-19 treatment scenarios are handled separately: only the limited, label-specified hospitalized adult use (when applicable per FDA labeling) is described in the exclusions, and changes to COVID-19-related language have been made in recent revisions to clarify which acute COVID-19 treatments fall outside the policy's scope.

Revision history explicitly removed the acute treatment of COVID-19 in hospitalized patients from the policy’s scope. This means the policy no longer attempts to provide coverage guidance for hospitalized COVID-19 acute therapy with tocilizumab; providers should reference product labeling and other COVID-19–specific guidance for those clinical scenarios.

Billing Codes, Dose Limits, and Coding Details

Considered Medically Necessary HCPCSHCPCSCovered

J3262

Injection, tocilizumab, 1 mg

Tocilizumab IV productsmixed

Avtozma

Added to policy with same criteria as other tocilizumab IV products

Per-dose maximum limits — mg/kg and absolute maximums (per indication)

Standard per-dose mg/kg limitsUp to 8 mg/kg per dose for most indications (patient ≥30 kg); some indications allow up to 12 mg/kg per dose for patients <30 kg

Common absolute per-dose maximumMaximum 800 mg per dose (specified for multiple indications including CRS and pediatric weight-based dosing)

Polymyalgia rheumatica & many other indicationsApprove dosing that meets BOTH: each dose up to 8 mg/kg to a max 800 mg; interval between doses commonly 4 weeks (some indications require 1 week or 4 weeks as noted)

Still's disease (adult and pediatric notes)Dosing guidance varies by age/indication: some sections specify up to 6 mg/kg max 600 mg (AOSD pediatric note) while others allow up to 8 mg/kg or 12 mg/kg for <30 kg—refer to indication-specific dosing

CRS associated with bispecific antibodiesEach dose: patient <30 kg — up to 12 mg/kg to a maximum 800 mg; patient ≥30 kg — up to 8 mg/kg to a maximum 800 mg; approve up to four doses with ≥8 hours between doses

Prior Authorization, Documentation, and Provider Requirements

Prior Authorization

Prior Authorization Required

Prior authorization is required for tocilizumab intravenous products (including J3262) and for Avtozma. Requests must meet indication-specific criteria, prescriber specialty requirements, dosing limits, and prior therapy requirements as outlined in the clinical criteria. Dosing limits include typical maximums (e.g., up to 8 mg/kg to a maximum of 800 mg per dose) and required minimum intervals between doses where specified.

Affected HCPCS: J3262 (tocilizumab, IV) and Avtozma (follow same IV criteria)
Prescriber specialty requirements apply for many indications (e.g., rheumatologist, oncologist/hematologist, pulmonologist, hepatologist, gastroenterologist, dermatologist, immunologist)
Dosing constraints and dose-interval requirements vary by indication (see dosing criteria)

Documentation Required

Documentation Requirements

Clinical documentation must demonstrate patient age, indication, prescriber specialty or consultation, prior therapy status (including required trials of systemic corticosteroids or other systemic therapies where specified), objective measures of response for continuation requests, and linkage of immunotherapy-related toxicities to checkpoint inhibitor therapy when applicable.

Background and Context

Tocilizumab is an interleukin‑6 receptor inhibitor used across a range of inflammatory and autoimmune conditions. The policy recognizes approved and supported uses including systemic juvenile idiopathic arthritis/adult‑onset Still’s disease (Still’s disease), Castleman disease, cytokine release syndrome associated with bispecific antibodies, graft‑versus‑host disease, immunotherapy‑related toxicities, polymyalgia rheumatica, and VEXAS syndrome. Dosing and approval durations vary by indication and weight, and objective measures (for example, laboratory markers or symptom improvement) are required for continuation determinations.

Definitions and Diagnostic Requirements

Still's disease (AOSD / SJIA) — definition and routing

DefinitionStill’s disease: Adult-onset Still’s disease (AOSD) and systemic juvenile idiopathic arthritis (SJIA) are considered the same disease differing by age of onset

Age-based routingFor patients ≥ 18 years of age, refer to the AOSD (adult-onset Still’s disease) indication; for patients < 18 years, refer to the SJIA indication

Prescriber requirementInitial therapy indications for Still’s disease (AOSD or SJIA) require the medication be prescribed by or in consultation with a rheumatologist

VEXAS (UBA1 variant) — diagnostic requirement for initial therapy

Genetic test requirementInitial therapy for VEXAS requires a molecular genetic test demonstrating a pathogenic or likely pathogenic UBA1 gene variant

Age criterion

Policy Revision History and Material Changes

2026-02-15Selected RevisionLatest

Avtozma added to policy with same criteria as other tocilizumab IV products; VEXAS syndrome added as a condition of approval; Castleman disease initial-therapy unicentric relapsed/refractory/progressive requirement removed.

2026-01-01Selected Revision

Graft‑Versus‑Host Disease added as a condition of approval; immunotherapy‑related toxicities expanded and documentation/objective measure guidance clarified (laboratory parameters such as liver function tests); Castleman disease initial-therapy requirements modified for unicentric vs multicentric disease.

Policy Summary

PayerCigna

PolicyTocilizumab Intravenous Products Prior Authorization Policy

Policy CodePolicy IP0656

Change TypeMultiple added and revised indicationscriteria clarifications

Effective DateFeb 15, 2026

Next Review DateN/A

Key ActionObtain prior authorization demonstrating the patient meets the specific indication criteria (age, prescriber specialty, prior therapy/trial status, and dosing limits).

SourceLink

On This Page

Objective measures referenced for some indications

Objective laboratory markersExamples include clinically significant improvement or normalization of serum markers such as C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR)

Clinical signs and symptom resolutionResolution of fever, improvement in rash or skin manifestations, decreased joint pain/tenderness, stiffness, swelling, decreased fatigue, or improved function/activities of daily living

Organ-specific measures for immunotherapy toxicitiesObjective measures are dependent upon organ involvement and may include laboratory parameters such as liver function tests for hepatic involvement

Use for continuation approvalsWhen assessing continuation, patient must show beneficial clinical response by at least one objective measure from baseline or improvement in at least one symptom compared with baseline

Denial Risk

Denial Risk for Noncompliant Requests

Requests that are inconsistent with the updated policy requirements may be denied. Examples include failure to meet revised corticosteroid trial language, lack of required prescriber specialty or consultation, absence of required prior systemic therapy where specified, or requests for dosing/intervals outside policy limits.

Denial risk if patient has not tried or is not currently taking required systemic corticosteroid when indicated (unless corticosteroids are contraindicated)
Denial risk for requests that do not document a prior trial of an indicated systemic medication (e.g., for graft-versus-host disease) or do not meet specialist prescriber requirements
Denial risk for dosing that exceeds policy maximums or fails to observe required minimum intervals between doses

Note

Conditions Not Covered

Tocilizumab intravenous products are considered not medically necessary for uses not listed in the policy. Specific exclusions include treatment of COVID-19 outside the policy's scope and concurrent use with another biologic or targeted synthetic oral small molecule drug for inflammatory conditions.

Not covered: Tocilizumab IV for COVID-19 treatment outside hospitalized adult indications described (policy does not address acute hospitalized COVID-19 treatment)
Not covered: Concurrent administration with another biologic or a targeted synthetic oral small molecule for inflammatory disease (conventional synthetic DMARDs such as methotrexate are not excluded)
Other off-label uses not supported by policy criteria are considered not medically necessary

Step Therapy

Prior Medication Trials Required for Some Indications

Some indications require prior medication trials before approval (examples shown below). Ensure documentation of these trials or documented contraindications.

Giant cell arteritis, polymyalgia rheumatica, and other rheumatologic indications: trial of or current use of a systemic corticosteroid unless contraindicated
Graft-versus-host disease: trial of at least one systemic medication for GVHD prior to tocilizumab initial therapy
Immunotherapy-related toxicities: trial of at least one systemic corticosteroid with documentation of inadequate response unless contraindicated
Still's disease (SJIA/AOSD): prior trial requirements vary by age and indication; biosimilars do not count toward biologic trial